Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

AC Immune S.A. (ACIU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 318,893
  • Shares Outstanding, K 67,562
  • Annual Sales, $ 7,360 K
  • Annual Income, $ -52,090 K
  • 60-Month Beta 0.04
  • Price/Sales 43.36
  • Price/Cash Flow N/A
  • Price/Book 1.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.33
  • Number of Estimates 2
  • High Estimate 1.74
  • Low Estimate 0.91
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +765.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.35 +8.51%
on 03/19/19
5.39 -12.38%
on 04/12/19
+0.09 (+1.94%)
since 03/18/19
3-Month
3.25 +45.23%
on 01/30/19
11.55 -59.13%
on 01/22/19
-6.62 (-58.38%)
since 01/18/19
52-Week
3.25 +45.23%
on 01/30/19
17.40 -72.87%
on 07/23/18
-5.30 (-52.89%)
since 04/18/18

Most Recent Stories

More News
Market Trends Toward New Normal in Radware, China Yuchai International, AC Immune SA, FTD Companies, Americas Silver, and NXT-ID -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Radware Ltd. (NASDAQ:RDWR), China...

ACIU : 4.72 (unch)
FTD : 0.44 (unch)
USAS : 1.68 (-4.55%)
RDWR : 26.10 (-0.42%)
NXTD : 0.93 (-0.79%)
CYD : 17.99 (-0.77%)
Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003

Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.

ACIU : 4.72 (unch)
ALEC : 22.47 (+4.37%)
LLY : 115.20 (-1.12%)
ABBV : 77.57 (-0.53%)
AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will present at the H.C. Wainwright...

ACIU : 4.72 (unch)
LLY : 115.20 (-1.12%)
Lilly (LLY) Signs New Immunology Deal With Private Biotech

Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.

ACIU : 4.72 (unch)
LLY : 115.20 (-1.12%)
ADRO : 3.38 (-0.88%)
SNY : 41.31 (+0.54%)
What Makes AC Immune (ACIU) a New Buy Stock

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ACIU : 4.72 (unch)
AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update

CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023

ACIU : 4.72 (unch)
LLY : 115.20 (-1.12%)
AC Immune to Report Progress of Early-Stage Pipeline at AD/PD(TM) Congress

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will provide oral presentations...

ACIU : 4.72 (unch)
Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?

Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.

ACIU : 4.72 (unch)
APTO : 1.83 (-1.08%)
BIO : 294.13 (+0.79%)
ADRO : 3.38 (-0.88%)
Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?

An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.

ACIU : 4.72 (unch)
APTO : 1.83 (-1.08%)
AMED : 117.22 (+1.37%)
ADRO : 3.38 (-0.88%)
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?

Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.

ACIU : 4.72 (unch)
TNDM : 54.41 (-1.63%)
MASI : 122.47 (+0.15%)
ADRO : 3.38 (-0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ACIU with:

Business Summary

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta...

See More

Key Turning Points

2nd Resistance Point 4.92
1st Resistance Point 4.82
Last Price 4.72
1st Support Level 4.60
2nd Support Level 4.47

See More

52-Week High 17.40
Fibonacci 61.8% 11.99
Fibonacci 50% 10.32
Fibonacci 38.2% 8.66
Last Price 4.72
52-Week Low 3.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar